Oruka Therapeutics, Inc.

ORKA

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$107.93

+$3.10 · +2.96%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

50/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Gaining

Sentiment

Bullish

Risk resilience

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Lawrence Otto Klein
Listed since: Aug 8, 1997
Employees: 68